FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Rinzimetostat | Metastatic Castration Resistant Prostate Cancer | PHASE3 | RECRUITING |
| Darolutamide | Metastatic Castration Resistant Prostate Cancer | PHASE3 | RECRUITING |
| Docetaxel | Metastatic Castration Resistant Prostate Cancer | PHASE3 | RECRUITING |
| Enzalutamide | Metastatic Castration Resistant Prostate Cancer | PHASE3 | RECRUITING |
| Nab-paclitaxel | Solid Tumor | PHASE1 | TERMINATED |
| ORIC-944 | Metastatic Prostate Cancer | PHASE1 | RECRUITING |
| ORIC-533 | Relapsed or Refractory Multiple Myeloma | PHASE1 | COMPLETED |
| ORIC-114 Dose 3 + amivantamab | Solid Tumors | PHASE1 | RECRUITING |
| ORIC-114 Dose 2 + amivantamab | Solid Tumors | PHASE1 | RECRUITING |
| ORIC-114 Dose 1 + amivantamab | Solid Tumors | PHASE1 | RECRUITING |
ORIC holds $37.5M in cash and burns about $32M/quarter from operations, giving an estimated runway of 3.5 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ORIC free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-07-28 | Heyman Richard A. |
Purchase | $72,480 |
| 2026-07-28 | Heyman Richard A. |
Sale | $460,366 |
| 2026-07-28 | Heyman Richard A. |
Sale | $2.5M |
| 2026-07-28 | Heyman Richard A. |
Sale | $0 |
| 2026-07-08 | Heyman Richard A. |
Sale | $2.6M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ORIC and 2 more tickers of your choice.
Create Free Account →